A 6-gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients

YAN LIU[1], DONGYAN ZHU[2], HONGJIAN XING[3], YI HOU[4] and YAN SUN[1]

Departments of [1]Anesthesiology, [2]Vascular Surgery, [3]Orthopedics and [4]Urology,
China Japan Union Hospital, Jilin University,
Changchun, Jilin 130033, P.R. China

Abstract. Pancreatic adenocarcinoma (PAC) is the most common type of pancreatic cancer, which commonly has an unfavorable prognosis. The present study aimed to develop a novel prognostic prediction strategy for PAC patients. mRNA sequencing data of PAC (the training dataset) were extracted from The Cancer Genome Atlas database, and the validation datasets (GSE62452 and GSE79668) were acquired from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) between good and poor prognosis groups were analyzed by limma package, and then prognosis-associated genes were screened using Cox regression analysis. Subsequently, the risk score system was constructed and confirmed using Kaplan-Meier (KM) survival analysis. After the survival associated-clinical factors were screened using Cox regression analysis, they were performed with stratified analysis. Using DAVID tool, the DEGs correlated with risk scores were conducted with enrichment analysis. The results revealed that there were a total of 242 DEGs between the poor and good prognosis groups. Afterwards, a risk score system was constructed based on 6 prognosis-associated genes (*CXCL11*, *FSTL4*, *SEZ6L*, *SPRR1B*, *SSTR2* and *TINAG*), which was confirmed in both the training and validation datasets. Cox regression analysis showed that risk score, targeted molecular therapy, and new tumor (the new tumor event days after the initial treatment according to the TCGA database) were significantly related to clinical prognosis. Under the same clinical condition, 6 clinical factors (age, history of chronic pancreatitis, alcohol consumption, radiation therapy, targeted molecular therapy and new tumor (event days) had significant associations with clinical prognosis. Under the same risk condition, only targeted molecular therapy was significantly correlated with clinical prognosis. In conclusion, the 6-gene risk score system may be a promising strategy for predicting the outcome of PAC patients.

Introduction

Pancreatic cancer (PC) originates from the pancreas, and the cancerous cells have the ability to invade other parts of the body (1). PC patients in early stages often do not have obvious signs or symptoms that are specific enough to suggest pancreatic cancer, and most patients are diagnosed with late stage disease or metastasis to other organs (2). Most cases of PC occur in individuals over the age of 70 years, and PC can be induced by diabetes, tobacco smoking, obesity, and genetic conditions (3,4). PC usually has a poor prognosis, and was responsible for 411,600 deaths globally in 2015 (5). The most common type of PC is pancreatic adenocarcinoma (PAC), which consists of ~85% of all PC cases (6). Therefore, it is important to determine new biological or pathological indicators related to the prognosis of PAC in addition to conventional prognostic approaches such as clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy (7).

In the past decade, research has uncovered the genes affecting the survival of PC patients. For example, genetic alterations and accumulation of cyclin-dependent kinase inhibitor 2A (*CDKN2A*)/*p16*, tumor protein p53 (*TP53*), and SMAD family member 4 (*SMAD4*)/*DPC4* are highly correlated with the malignant potential of PAC, and their expression levels may predict the prognosis of PAC patients (8). B-cell-specific Moloney murine leukemia virus insertion site 1 (*BMI1*) is reported to be significantly upregulated in PC, and its expression has a positive association with lymph node metastases and a negative correlation with the survival rates of PC patients (9,10). The expression levels of aldehyde dehydrogenase 1 family, member A1 (*ALDH1A1*) (11,12) and insulin-like growth factor 2 mRNA binding protein 3 (*IGF2BP3*) could be used to predict the prognosis of PAC (13). Overexpression of homeo box B7 (*HOXB7*) contributes to the invasive behavior of PAC (14,15). Nevertheless, the prognostic mechanisms of PAC warrant further investigation.

Bioinformatic analysis is a new way for revealing the pathogenesis of diseases and identifying novel therapeutic

Correspondence to: Dr Yan Sun, Department of Anesthesiology, China Japan Union Hospital, Jilin University, 126 Xiantai Street, Changchun, Jilin 130033, P.R. China
E-mail: smartloft@sina.com

Table I. Clinical information of The Cancer Genome Atlas (TCGA) dataset and the validation datasets (GSE79668 and GSE62452).

Clinical factors	TCGA (n=178)	GSE79668 (n=51)	GSE62452 (n=69)
Age, years (mean ± SD)	64.69±11.09	64.04±11.57	-
Sex (male/female/-)	91/74/13	32/19	-
Chronic pancreatitis history (yes/no/-)	13/117/48	-	-
Diabetes history (yes/no/-)	36/99/43	22/29	-
Alcohol (yes/no/-)	97/57/24	-	-
Tobacco (never/reform/current/-)	59/56/19/44	-	-
New tumor (yes/no/-)	55/101/22	-	-
Pathologic_M (M0/M1/-)	75/3/100	48/1/2	-
Pathologic_N (N0/N1/-)	44/117/17	14/37	-
Pathologic_T (T1/T2/T3/T4/-)	8/19/134/3/14	3/12/31/5	-
Pathologic_stage (I/II/III/IV/-)	20/137/4/3/	-	4/46/13/6
Radiation therapy (yes/no/-)	38/107/33		-
Targeted molecular therapy (yes/no/-)	102/48/28		-
Deceased (death/alive/-)	83/8213	45/6	49/16/4
Overall survival months (mean ± SD)	17.11±15.35	26.78±26.12	20.21±16.69

-, Indicates information unavailable. SD, standard deviation.

targets (16). To screen the key genes correlated with the prognosis of PAC and develop novel prognostic prediction strategies, we downloaded and analyzed the public datasets of PAC. Through a series of bioinformatic analyses, a risk score system of PAC was constructed and assessed in the present study. The present study may provide a novel means for predicting the outcome of PAC patients and helping in selecting appropriate therapeutic methods.

Materials and methods

Data source. The mRNA sequencing data of PAC (the training dataset; platform: Illumina HiSeq 2000 RNA Sequencing; downloaded in March 30, 2017; including 178 PAC samples) and correlative clinical information were extracted from The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) database. Meanwhile, 'PAC' was used as the search words for selecting relevant datasets from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database. The inclusive criteria were as follows: i) the samples were human tissues (not cell lines); ii) the samples were provided with prognostic information. Finally, GSE79668 (17) [platform: GPL11154 Illumina HiSeq 2000 (*Homo sapiens*); 51 samples] and GSE62452 (18) [platform: GPL6244 (HuGene-1_0-st) Affymetrix Human Gene 1.0 ST Array (transcript (gene) version); 69 samples] were selected and considered as the validation datasets. The clinical information of the training dataset and the validation datasets are presented in Table I.

Differential expression analysis. Among the 178 PAC samples in the training dataset, 163 PAC samples had prognostic information. The 17 PAC samples with follow-up time <6 months whose status was still alive at the last follow-up were considered as ineligible samples since the actual survival time was unknown (data not available) due to loss

Table II. The 6 prognosis-associated genes to establish the risk score system.

Genes	coef	HR	P-value
CXCL11	0.451453	0.6367	0.0031
FSTL4	0.54981	0.5771	0.0025
SEZ6L	-1.18976	3.2863	<0.0001
SPRR1B	0.37643	0.6863	0.0004
SSTR2	1.17541	0.3087	0.0035
TINAG	0.26515	0.7671	0.0163

HR, hazard ratio.

of follow-up. Then, these 17 ineligible samples were removed for analysis in our study. Afterwards, the remained 146 PAC samples were divided into good prognosis and poor prognosis groups. The PAC samples obtained from living patients with a survival time >24 months were classified into a good prognosis group, and the PAC samples obtained from deceased patients with a survival time <6 months were classified into the poor prognosis group. Under the thresholds of false discovery rate (FDR) <0.05 and |logfold change (FC)| >0.585, the differentially expressed genes (DEGs) between the good and poor prognosis groups were analyzed using the R package limma (http://www.bioconductor.org/packages/release/bioc/html/limma.html) (19).

Identification of prognosis-associated gene. The 146 PAC samples were applied for identifying prognosis-associated genes. Using univariate and multivariate Cox regression analyses in R package survival (20), prognosis-associated

Table III. Cox regression analysis for selecting the clinical factors significantly related to prognosis.

Clinical characteristics	Univariable Cox P-value	Multivariable Cox P-value
Age in years (above/below median)	0.0781	
Sex (male/female)	0.5630	
Pathologic_M (M0/M1)	0.3020	
Alcohol (yes/no)	0.8190	
Tobacco (never/reform/current)	0.1490	
Chronic pancreatitis history (yes/no)	0.6990	
Diabetes history (yes/no)	0.6830	
Pathologic_N (N0/N1)	0.0128	0.2683
Pathologic_T (T1/T2/T3/T4)	0.0338	0.2258
Radiation therapy (yes/no)	0.0371	0.5174
New tumor (yes/no)	**0.0107**	**0.0269**
Targeted molecular therapy (yes/no)	**0.0010**	**<0.0001**
Risk score	**<0.0001**	**<0.0001**

P-values in bold print indicate significant correlations.

genes were selected from the DEGs. Then, significant P-values were obtained by log-rank test (21), and P-value <0.05 was taken as the threshold for screening prognosis-associated genes.

Construction and assessment of risk score system. Based on the prognosis-associated genes, a risk score system was constructed for the PAC patients. Firstly, the identified prognostic-associated genes were sorted by their individual P-value of the Cox regression analysis. Each gene was added one at a time in the risk score system, and the risk scores of the included gene were summed. This procedure was repeated until all the prognostic-associated genes were included. Finally, a set of minimum number of genes having the smallest P-value were selected for constructing the risk score system. Risk scores were obtained based on the linear combination of the gene expression values experiencing regression coefficient weighting. The risk score for each patient was calculated as the sum of each gene's score, which was obtained by multiplying the expression level of a gene by its corresponding coefficient (β)s using the following formula:

$$\text{Risk score} = \beta \text{gene1} \times \text{Exp gene1} + \beta \text{gene2} \times \text{Exp gene2} + \cdots + \beta \text{gene(n)} \times \text{Exp gene(n)}$$

Subsequently, the risk of the PAC patients in the validation datasets were assessed using the β value acquired from the training dataset. Meanwhile, the differences in survival ratio were analyzed between high- and low-risk groups which were divided using the median cut-off of the risk scores as the threshold with log-rank test in Kaplan-Meier (KM) survival analysis. The differences between the low-risk and high-risk groups for expressions of the 6 genes were compared with t-test.

Correlation analysis between risk score system and clinical factors. Using the risk score system, risk scores were

calculated for the samples in the training and validation datasets. According to the median of the risk scores, the samples were divided into high- and low-risk groups. Based on the clinical information corresponding to the samples, COX regression analysis (22) was used to perform correlation analysis for screening the survival associated-clinical factors.

Stratified analysis. Furthermore, stratified analysis was performed for the survival associated-clinical factors based on the following strategies: i) under the same clinical condition, the correlation between survival prognosis and high-/low-risk groups was analyzed; and ii) under the same risk condition, the correlation between survival prognosis and different clinical conditions was analyzed.

Enrichment analysis. According to the risk scores, the samples were classified into high- and low-risk groups. For the training dataset, the DEGs between high and low risk groups were identified using limma package (19). The DEGs were defined as genes with FDR <0.05. Afterwards, correlation analysis for the DEGs and risk scores were conducted. To screen significantly enriched biological processes and pathways, the DEGs positively and negatively related to risk scores were conducted with enrichment analysis using DAVID tool (https://david.ncifcrf.gov/) (23).

Results

Differential expression analysis. Among the 146 PAC samples, 18 and 19 PAC samples separately were divided into poor and good prognosis groups. Under the screening thresholds, 242 DEGs between the two groups were selected.

Construction and assessment of risk score system. Based on univariate Cox regression analysis, 165 prognosis-associated genes were selected. Moreover, the 165 prognosis-associated genes were conducted with multivariate Cox regression analysis

Figure 1. Overall survival of pancreatic adenocarcinoma (PAC) patients in low- and high-risk groups in The Cancer Genome Atlas (TCGA) dataset (A), GSE62452 (B), and GSE79668 (C). Red and black separately represent high- and low-risk groups.

and 8 prognosis-associated genes were further screened. Finally, 6 prognosis-associated genes [chemokine (C-X-C motif) ligand 11], *CXCL11*; follistatin-like 4, *FSTL4*; seizure related 6 homolog (mouse)-like, *SEZ6L*; small proline-rich protein 1B, *SPRR1B*; somatostatin receptor 2, *SSTR2*; and tubulointerstitial nephritis antigen, *TINAG*) were selected for constructing the risk score system (Table II). The formula was as follows:

$$\text{Risk score} = 0.451 \times \text{Exp CXCL11} + 0.5498 \times \text{Exp FSTL4} + (-1.1897) \times \text{Exp SEZ6L} + 0.376 \times \text{Exp SPRR1B} + 1.175 \times \text{Exp SSTR2} + 0.265 \times \text{Exp TINAG}$$

The risk scores were calculated for the samples using the risk score system. Afterwards, the 6 prognosis-associated genes were utilized for performing risk evaluation for the PAC patients. According to the median risk scores, the patients in the training dataset were classified into high-(83 patients) and low-(83 patients) risk groups. In relation to the high-risk group with the average overall survival (OS) time of 16.88±14.92 months, the low-risk group with the average OS time of 18.84±13.91 months had a higher survival ratio (P<0.0001; Fig. 1A). For the validation dataset GSE62452, the low-risk group (24 patients; average OS time=25.1±18.79 months) also had a higher survival ratio (P=0.0465) in comparison with the high-risk group (25 patients; average OS time=16.78±16.21 months) (Fig. 1B). For the validation dataset GSE79668, the low-risk group (25 patients; average OS time=37.07±32.15 months) had a higher survival ratio (P=0.0374) compared with the high-risk group (26 patients; average OS time=17.55±15.50 months) (Fig. 1C). The expression distributions of the 6 prognosis-associated genes in the high- and low-risk groups of the 3 datasets are exhibited in Fig. 2. The expression levels of *SPRR1B*, *TINAG* and *CXCL11* were significantly lower, those of *SEZ6L* and *SSTR2* were higher in the low-risk group of The Cancer Genome Atlas (TCGA) dataset (Fig. 2A). However, an obviously decreased expression level of SSTR2 was observed in the low-risk group of GSE62452 (Fig. 2B) which may be due to the fact that the gene expression model in the validation datasets could not be exactly the same as those in the training dataset.

Correlation analysis between risk score system and clinical factors. The clinical factors significantly related to prognosis were selected by Cox regression analysis. Our results


Figure 2. Expression distributions of the 6 prognosis-associated genes in the high- and low-risk groups of The Cancer Genome Atlas (TCGA) dataset (A), GSE62452 (B) and GSE79668 (C). *0.01≤P<0.05; **0.005≤P<0.01; ***P<0.005.

showed that risk score, targeted molecular therapy, and new tumor (event days) were significantly correlated with survival time (Table III). According to different clinical factors, the samples were divided into groups and then differential expression analysis was conducted (Table IV).

Stratified analysis. Correlation analysis under the same clinical condition showed that 6 clinical factors (age, chronic pancreatitis history, alcohol consumption, radiation therapy, targeted molecular therapy, and new tumor) under different groups were significantly correlated with survival time (Table V). Moreover, these 6 clinical factors were used to perform Kaplan-Meier (KM) survival analysis in the different groups (Fig. 3).

Table IV. Results of differential expression analysis after dividing the samples into groups according to different clinical factors.

Clinical factors	Downregulated genes	Upregulated genes
Age in years (above vs. below median)	WBSCR26, TRIM54, ARX, SERPINA4, MT1H, AQP5, PRSS21, MSLN, APOBEC1, CALHM3	NTSR1, SPRR3, KLK10, SPRR1A, ALDH3A1, SERPINB3, CXCL17, SPRR1B, KLK1, SYCN, TRY6, CELA2B, PNLIPRP2, CLPS, CELA3A, REG1A, CELA3B, PNLIP, CELA2A
Sex (male vs. female)	NLRP2	HOXA13, UPK1B
Chronic pancreatitis history (yes vs. no)	PNLIP, PNLIPRP1, CPA1, CELA2A, CLPS, CELA2B, TRY6, REG3G, CELA3B, SYCN, TDRD9, ARX, KCNJ3, KIAA1409, ST18, TMEM132D, KCNMB2, SYT4	PLEKHN1, POU2F3, CATSPER1, ABCA12, GPR110, WBSCR26, UGT1A6, HOXB9, MYEOV, S100P, GJB5, GJB4, GJB3, SFTPA2, NMU
Diabetes history (yes vs. no)	ABCA13	NMUR2
Alcohol (yes vs. no)	S100A2	C5orf49
Tobacco (never vs. reform)	-	-
Tobacco (never vs. current)	PPP1R1A, CRYBA2, SEZ6L, RIMBP2, LHFPL4, VWA5B2, PCSKIN, HMGCLL1, GRM4, ARX, TMEM63C, ASTN1, TCEAL2, LRRC10B, SSTR2, DUSP26, C1QL1, GCK, SNAP91, CACNA1A, JPH3, MSI1	GPR110, DKK1, MUC4, SERPINB4, SERPINB3, MUC16
Pathologic_M (M0 vs. M1)	-	-
Pathologic_T (T1+ T2 vs. T3+T4)	SYT4GPR98, SPTBN4, CELF4, ASTN1, CHD5, UNC13A, HAP1, HMGCLL1, FBLL1, PTPRT, LRRC24, ATP1A3, APOH, MSI1, PIPOX, LRRC4B, HPCA,	KPNA7, HOXA13, DSG3, UPK1B, AKR1B10
Pathologic_N (N0 vs. N1)	LOC389332, GRM4, LRRC16B	MMP3, AIM2, HOXA13, ABCA13, CXCL11, EGF, GJB4, PIK3C2G, AKR1B10, ITGB6, C12orf36, KRT5, NMUR2, SERPINA4, UPK1B, GABRP, CXCL5, REG3G, CTRC, PNLIPRP1
Radiation therapy (yes vs. no)	LOC554202, TNS4	AIM2
Targeted molecular therapy (yes vs. no)	ZNF683, KPNA7, RASEF, MT1H, GPR110, SERPINA4, EGF, UPK1B, KLK1, TRY6, CELA2B, SYCN	PNLIPRP2, PNLIPRP1, REG1A, CLPS, REG3G, CELA3B, CELA2A, REG1B, PNLIP, CTRC, CPA1, CELA3A, CTRB2
New tumor (yes vs. no)	LOC389332, LRRC16B, FFAR2, PIPOX, RAB3C, JPH3	CDSN, PLEKHN1, ABCA13, WBSCR26, TMEM105, GPR1, FAM83B, GJB4, CYP27C1, GJB5, LOC554202, FGFBP1, ABCA12

Tobacco: current, subjects who smoke at least once a month; reform, those who have tried smoking but have quit; never, those who have never tried tobacco). Pathologic_M: M1, distant metastasis. Pathologic_T: T1, unilateral tumor 80 cm² or less in area; T2, unilateral tumor more than 80 cm² in area; T3, unilateral tumor rupture before treatment; T4, bilateral tumors. Pathologic_N: N0, no regional lymph node metastasis; N1, regional lymph node metastasis. New tumor, tumor metastasis or spread to other parts of the body.

Figure 3. The Kaplan-Meier (KM) survival curves for the 6 clinical factors (age, alcohol use, new tumor, targeted molecular therapy, chronic pancreatitis history and radiation therapy) in high- and low-risk groups under the same clinical condition. (A) Survival curves for patients below the age of 65 (left), patients above the age of 65 (middle), and patients below or above the age of 65 years (right). (B) The survival curves for no-alcohol group (left), alcohol group (middle), and no-alcohol or alcohol groups (right). (C) Survival curves for no new tumor group (left), new tumor group (middle), and no new tumor or new tumor groups (right). (D) Survival curves for no targeted therapy group (left), targeted therapy group (middle), and no targeted therapy or targeted therapy groups (right). (E) Survival curves for no chronic pancreatitis group (left), chronic pancreatitis group (middle), and no chronic pancreatitis or chronic pancreatitis groups (right). (F) Survival curves for no radiation therapy group (left), radiation therapy group (middle), and no radiation therapy or radiation therapy groups (right). Red and black separately represent high- and low-risk groups.

Table V. Results of the stratified analysis under the same clinical condition.

Clinical factors	P-value
Age (≥65 years, n=75)	0.0526
Age (<65 years, n=76)	0.0011
Sex (male, n=85)	0.2520
Sex (female, n=64)	0.7210
Chronic pancreatitis history (yes, n=13)	0.6360
Chronic pancreatitis history (no, n=109)	<0.0001
Diabetes history (yes, n=32)	0.1200
Diabetes history (no, n=94)	0.0936
Alcohol (yes, n=90)	0.0018
Alcohol (no, n=51)	0.0071
Tobacco (never, n=54)	0.3370
Tobacco (reform, n=53)	0.0502
Tobacco (current, n=17)	0.1180
Pathologic_M (M0, N=68)	0.6310
Pathologic_M (M1, n=2)	-
Pathologic_N (N0, n=40)	0.1930
Pathologic_N (N1, n=105)	0.0537
Pathologic_T (T1+T2, n=24)	0.1540
Pathologic_T (T3+T4, n=124)	0.0567
Radiation therapy (yes, n=37)	0.0215
Radiation therapy (no, n=102)	0.0021
Targeted molecular therapy (yes, n=98)	0.0357
Targeted molecular therapy (no, n=45)	0.0019
New tumor (yes, n=54)	0.0357
New tumor (no, n=87)	0.0193

Table VI. Results of the stratified analysis under the same risk condition.

Clinical factors	High risk	Low risk
Age in years (above vs. below median)	0.888	0.056
Sex (male vs. female)	0.622	0.939
Pathologic_M (M0/M1)	0.869	0.368
Pathologic_N (N0 vs. N1)	0.332	0.906
Pathologic_T (T1 vs. T2 vs. T3)	0.308	0.098
Chronic pancreatitis history (yes vs. no)	0.267	0.917
Diabetes history (yes vs. no)	0.643	0.997
Alcohol (yes vs. no)	0.803	0.977
Tobacco (never vs. reform vs. current)	0.210	0.534
Radiation therapy (yes vs. no)	0.668	0.173
Targeted molecular therapy (yes vs. no)	0.002	0.154
New tumor (yes vs. no)	0.389	0.997

Under the same risk condition, the correlation analysis suggested that targeted molecular therapy had significant association with clinical prognosis (Table VI). KM survival analysis was also performed for targeted molecular therapy under different groups (Fig. 4). Meanwhile, the risk scores and survival time of the patients, and the expression heatmaps of the 6 prognosis-associated genes are presented in Fig. 5.

Enrichment analysis. For the training set, there were 373 DEGs between the high- and low-risk groups. Correlation analysis showed that 179 and 194 DEGs separately were positively and negatively related to risk scores. Then, the top 20 DEGs were selected and conducted with clustering analysis (Fig. 6A). Additionally, multiple significantly enriched biological processes (Fig. 6B) and pathways (Fig. 6C) were obtained for these DEGs.

Discussion

In the present study, a total of 242 DEGs between the poor and good prognosis groups were selected. Then, 6 prognosis-associated genes (*CXCL11*, *FSTL4*, *SEZ6L*, *SPRR1B*, *SSTR2* and *TINAG*) were selected for constructing a risk score system. The expression levels of SSTR2 were higher in the low-risk group of the TCGA dataset and GSE79668, while an obviously decreased expression level of SSTR2 was observed in the low-risk group of GSE62452. This discrepancy may be due to the fact that the gene expression model in the validation datasets could not be exactly the same as those in the training dataset. The patients in the TCGA training dataset and validation datasets (GSE62452 and GSE79668) were classified into high- and low-risk groups according to the median of risk scores which were calculated according to not only the expression levels of the 6 genes but also their regression coefficients. Moreover, the risk score system was confirmed in both the training and the two validation (GSE62452 and GSE79668) datasets, suggesting that the constructed 6-gene risk score system has prognostic prediction value. Therefore, it is necessary to select SSTR2 to build the 6-gene risk score system. Cox regression analysis showed that risk score and new tumor were significantly correlated with survival time. Under the same clinical condition, 6 clinical factors were significantly correlated with survival time. Although only targeted molecular therapy had a significant association with clinical prognosis under the same risk condition, the clinical impact was still unexplainable when various types of molecular-targeted agents were mixed. However, this association analysis was not performed since the specific method of targeted-therapy for each patient is unavailable from The Cancer Genome Atlas. In addition, multiple significantly enriched biological processes and pathways for the genes positively or negatively related to risk scores were obtained.

Angiogenesis is a typical feature of tumor cell growth, and the CXC chemokines have pleiotropic abilities in mediating tumor-correlated angiogenesis and tumor metastasis (24,25). Chemokine receptors chemokine (C-X-C motif) receptor 4 (*CXCR4*) and *CXCR7* are co-expressed in PC samples (26). *CXCL14* is highly expressed in PC tissues suggesting its correlation with the pathogenesis of PC (27). *FSTL1* was found to have a low expression in PC, and inhibits the cell growth and proliferation in PC patients (28,29). The expression of *SSTR2* is lost in the process of PAC development, which contributes to tumor cell growth via the activation

Figure 4. Kaplan-Meier (KM) survival curves for targeted molecular therapy in the high- and low-risk groups under the same risk condition. (A) Survival curve for no targeted therapy group. (B) Survival curve for targeted therapy group. (C) Survival curve for no targeted therapy or targeted therapy groups. Red and black separately represent high- and low-risk groups.


Figure 5. Risk scores and survival time of the patients, as well as the expression heatmaps of the 6 prognosis-associated genes separately in The Cancer Genome Atlas (TCGA) dataset (A), GSE79668 (B) and GSE62452 (C).


Figure 6. Clustering heatmap for the top 20 differentially expressed genes (DEGs) positively or negatively related to risk scores (A), and the significantly enriched biological processes (B) and pathways (C) for the risk score-associated DEGs.

of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling and the overexpression of *CXCL16* (30). *SSTR2* plays antitumor roles in PC, and its re-expression via gene transfer may be a promising gene therapy approach for the disease (31,32). Therefore, *CXCL11*, *FSTL4* and *SSTR2* may be related to the mechanisms of PAC.

However, little research has reported the involvement of *SEZ6L*, *SPRR1B* and *TINAG* in PAC. As a transmembrane protein with multiple domains, SEZ6L protein plays roles in signal transduction and protein-protein interaction (33). *SEZ6L* expression is elevated in lung cancer tissues, and *SEZ6L* variants are correlated with the progression of lung cancer and can increase the risk of the disease (34,35). The mRNA expression of *SPRR1* is caused before the formation of Chinese hamster ovary (CHO) cells in G_0 phase, and thus *SPRR1* expression is responsive to growth-arresting signals (36). As a basement membrane glycoprotein, *TINAG* can be recognized by autoantibodies in some types of human tubulointerstitial nephritis (37). The TINAG-related protein (*TINAG-RP*) was found to have higher expression levels in a colorectal adenocarcinoma cell line (38). *SEZ6L*, *SPRR1B* and *TINAG* play roles in other types of malignant tumors, indicating that they may also function in the development and progression of PAC.

Furthermore, the following limitations should be mentioned in this study. On the one hand, the prognostic prediction model based on the expression levels of these 6 prognosis-associated genes should be validated in an independent patient cohort by clinical experiments. Whether our model is superior to conventional prognostic factors still needs to be explored based on more research. On the other hand, the prediction accuracy of the risk score system may be influenced by data heterogeneity, platform differences and sample size differences of the training and validation datasets. Thus, further experiments are still needed to confirm these results.

In conclusion, 242 DEGs between the poor and good prognosis groups were screened, and 6 prognosis-associated genes (*CXCL11*, *FSTL4*, *SEZ6L*, *SPRR1B*, *SSTR2* and *TINAG*) were selected for constructing a risk score system. Moreover, the 6-gene risk score system may be utilized for predicting the clinical prognosis of PAC patients. However, further research is still needed to validate the prognostic prediction value based on the expression levels of these 6 prognosis-associated genes in an independent patient cohort with PAC.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

YL performed the data analyses and wrote the manuscript. DZ, HX and YH contributed significantly in data analyses and manuscript revision. YS conceived and designed the study. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

In the original article of the datasets, the trials were approved by the local institutional review boards of all participating centers, and informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Husain K: Pancreatic cancer treatment. Cancer Sci 5: 1100-1100, 2014.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Maisonneuve P and Lowenfels AB: Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int J Epidemiol 44: 186-198, 2015.
4. Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209, 2006.
5. McGuire S: World cancer report 2014. Geneva, Switzerland: World health organization, international agency for research on cancer, WHO Press, 2015. Adv Nutr 7: 418-419, 2016.
6. Bond-Smith G, Banga N, Hammond TM and Imber CJ: Pancreatic adenocarcinoma. BMJ 344: e2476, 2012.
7. Yeo CJ and Cameron JL: Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 383: 129-133, 1998.
8. Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y and Yachida S: Immunohistochemically detected expression of 3 major genes (*CDKN2A/p16*, *TP53*, and *SMAD4/DPC4*) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258: 336-346, 2013.
9. Song W, Tao K, Li H, Jin C, Song Z, Li J, Shi H, Li X, Dang Z and Dou K: Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101: 1754-1760, 2010.
10. Proctor E, Waghray M, Lee CJ, Heidt DG, Yalamanchili M, Li C, Bednar F and Simeone DM: Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One 8: e55820, 2013.
11. Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E, Dutta S, Niemietz T, Koch M and Weitz J: Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer 11: 275, 2011.
12. Hoshino Y, Nishida J, Katsuno Y, Koinuma D, Aoki T, Kokudo N, Miyazono K and Ehata S: Smad4 decreases the population of pancreatic cancer-initiating cells through transcriptional repression of *ALDH1A1*. Am J Pathol 185: 1457-1470, 2015.
13. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10: 59, 2010.
14. Nguyen Kovochich A, Arensman M, Lay AR, Rao NP, Donahue T, Li X, French SW and Dawson DW: HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer 119: 529-539, 2013.
15. Chile T, Fortes MA, Corrêa-Giannella ML, Brentani HP, Maria DA, Puga RD, de Paula Vde J, Kubrusly MS, Novak EM, Bacchella T, *et al*: HOXB7 mRNA is overexpressed in pancreatic ductal adenocarcinomas and its knockdown induces cell cycle arrest and apoptosis. BMC Cancer 13: 451, 2013.
16. Zhang Y, Szustakowski J and Schinke M: Bioinformatics analysis of microarray data. Methods Mol Biol 573: 259-284, 2009.
17. Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, *et al*: RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for *ANGPTL4*. Mol Oncol 10: 1169-1182, 2016.

18. Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, *et al*: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res 76: 3838-3850, 2016.
19. Smyth GK: Limma: Linear models for microarray data. Bioinformatics Comput Biol Solutions Using R and Bioconductor: 397-420, 2005.
20. Therneau T: A package for survival analysis. R package 2.37-2. 2012.
21. Kleinbaum DG and Klein M: Kaplan-meier survival curves and the log-rank test. Statistics Biol Health: 45-82, 2012.
22. Gui J and Li H: Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics 21: 3001-3008, 2005.
23. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183, 2007.
24. Keeley EC, Mehrad B and Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106: 91-111, 2010.
25. Keeley EC, Mehrad B and Strieter RM: Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res 317: 685-690, 2011.
26. Heinrich EL, Lee W, Lu J, Lowy AM and Kim J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med 10: 68, 2012.
27. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW and Friess H: CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259: 209-217, 2008.
28. Viloria K, Munasinghe A, Asher S, Bogyere R, Jones L and Hill NJ: A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth. Sci Rep 6: 37839, 2016.
29. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P and Michel MS: Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 25: 183-191, 2005.
30. Chalabidchar M, Cassantsourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, *et al*: Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16. Gastroenterology 148: 1452-1465, 2015.
31. Du ZY, Qin RY, Xia W, Tian R and Kumar M: Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts. World J Gastroenterol 11: 516-520, 2005.
32. Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L and Cordelier P: Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Human Gene Ther 16: 1175-1193, 2005.
33. Pigoni M, Wanngren J, Kuhn PH, Munro KM, Gunnersen JM, Takeshima H, Feederle R, Voytyuk I, De Strooper B, Levasseur MD, *et al*: Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener 11: 67, 2016.
34. Nishioka M, Kohno T, Takahashi M, Niki T, Yamada T, Sone S and Yokota J: Identification of a 428-kb homozygously deleted region disrupting the *SEZ6L* gene at 22q12.1 in a lung cancer cell line. Oncogene 19: 6251-6260, 2000.
35. Gorlov IP, Meyer P, Liloglou T, Myles J, Boettger MB, Cassidy A, Girard L, Minna JD, Fischer R, Duffy S, *et al*: *Seizure 6-like* (*SEZ6L*) gene and risk for lung cancer. Cancer Res 67: 8406-8411, 2007.
36. Tesfaigzi Y, Wright PS and Belinsky SA: SPRR1B overexpression enhances entry of cells into the G_0 phase of the cell cycle. Am J Physiol Lung Cell Mol Physiol 285: L889-L898, 2003.
37. Yoshioka K, Takemura T and Hattori S: Tubulointerstitial nephritis antigen: Primary structure, expression and role in health and disease. Nephron 90: 1-7, 2002.
38. Wex T, Lipyansky A, Brömme NC, Wex H, Guan XQ and Brömme D: TIN-ag-RP, a novel catalytically inactive cathepsin B-related protein with EGF domains, is predominantly expressed in vascular smooth muscle cells. Biochemistry 40: 1350-1357, 2001.